| Characteristic | No. (%) of patients* n = 2050 | |
|---|---|---|
| Age, yr, median (IQR) | 72 (58-82) | |
| Sex, male | 1056 | (51.5) |
| Serum creatinine level, μmol/L, median (IQR)† | 78 (62-99) | |
| Anticoagulant | ||
| None | 1679 | (81.9) |
| Warfarin | 315 | (15.4) |
| Dabigatran | 16 | (0.8) |
| Rivaroxaban | 4 | (0.2) |
| Apixaban | 0 | |
| Low-molecular-weight heparin | 35 | (1.7) |
| Fondaparinux | 1 | (0.05) |
| Antiplatelet | ||
| None | 1516 | (74.0) |
| Acetylsalicylic acid | 436 | (21.3) |
| Clopidogrel | 50 | (2.4) |
| Prasugrel | 1 | (0.05) |
| Dual antiplatelets | 47 | (2.3) |
| Combinations | ||
| Antiplatelet and anticoagulant | 94 | (4.6) |
| Antiplatelet or anticoagulant | 811 | (39.6) |
| Bleeding site | ||
| Intracerebral | 753 | (36.7) |
| Subarachnoid | 460 | (22.4) |
| Subdural | 750 | (36.6) |
| Epidural | 1 | (0.05) |
| Intraventricular | 11 | (0.5) |
| ≥ 1 site | 73 | (3.6) |
Note: IQR = interquartile range.
*Unless stated otherwise.
†54/2050 patients had no serum creatinine measurement.